Suppr超能文献

西格玛受体作为神经保护的潜在治疗靶点。

Sigma receptors as potential therapeutic targets for neuroprotection.

作者信息

Nguyen Linda, Kaushal Nidhi, Robson Matthew J, Matsumoto Rae R

机构信息

Graduate Program in Pharmaceutical and Pharmacological Sciences, West Virginia University, Morgantown, WV 26506, USA.

Graduate Program in Pharmaceutical and Pharmacological Sciences, West Virginia University, Morgantown, WV 26506, USA.

出版信息

Eur J Pharmacol. 2014 Nov 15;743:42-7. doi: 10.1016/j.ejphar.2014.09.022. Epub 2014 Sep 27.

Abstract

Sigma receptors comprise a unique family of proteins that have been implicated in the pathophysiology and treatment of many central nervous system disorders, consistent with their high level of expression in the brain and spinal cord. Mounting evidence indicate that targeting sigma receptors may be particularly beneficial in a number of neurodegenerative conditions including Alzheimer׳s disease, Parkinson׳s disease, stroke, methamphetamine neurotoxicity, Huntington׳s disease, amyotrophic lateral sclerosis, and retinal degeneration. In this perspective, a brief overview is given on sigma receptors, followed by a focus on common mechanisms of neurodegeneration that appear amenable to modulation by sigma receptor ligands to convey neuroprotective effects and/or restorative functions. Within each of the major mechanisms discussed herein, the neuroprotective effects of sigma ligands are summarized, and when known, the specific sigma receptor subtype(s) involved are identified. Together, the literature suggests sigma receptors may provide a novel target for combatting neurodegenerative diseases through both neuronal and glial mechanisms.

摘要

西格玛受体构成了一个独特的蛋白质家族,鉴于它们在大脑和脊髓中的高表达水平,其与许多中枢神经系统疾病的病理生理学及治疗有关。越来越多的证据表明,靶向西格玛受体在包括阿尔茨海默病、帕金森病、中风、甲基苯丙胺神经毒性、亨廷顿病、肌萎缩侧索硬化症和视网膜变性在内的多种神经退行性疾病中可能特别有益。从这个角度出发,本文首先对西格玛受体进行简要概述,然后重点关注那些似乎可通过西格玛受体配体调节以传递神经保护作用和/或恢复功能的神经退行性变的常见机制。在本文讨论的每一种主要机制中,总结了西格玛配体的神经保护作用,并在已知的情况下,确定所涉及的特定西格玛受体亚型。综合来看,文献表明西格玛受体可能通过神经元和神经胶质机制为对抗神经退行性疾病提供一个新靶点。

相似文献

1
Sigma receptors as potential therapeutic targets for neuroprotection.
Eur J Pharmacol. 2014 Nov 15;743:42-7. doi: 10.1016/j.ejphar.2014.09.022. Epub 2014 Sep 27.
2
Role of sigma-1 receptors in neurodegenerative diseases.
J Pharmacol Sci. 2015 Jan;127(1):17-29. doi: 10.1016/j.jphs.2014.12.005. Epub 2014 Dec 11.
4
Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain.
Expert Opin Ther Targets. 2020 Oct;24(10):1009-1028. doi: 10.1080/14728222.2020.1805435. Epub 2020 Aug 31.
5
The Role of Sigma 1 Receptor as a Neuroprotective Target in Glaucoma.
Adv Exp Med Biol. 2017;964:299-307. doi: 10.1007/978-3-319-50174-1_20.
6
Sigma-1 (σ) Receptor in Memory and Neurodegenerative Diseases.
Handb Exp Pharmacol. 2017;244:81-108. doi: 10.1007/164_2017_15.
7
Sigma (σ) receptors as potential therapeutic targets to mitigate psychostimulant effects.
Adv Pharmacol. 2014;69:323-86. doi: 10.1016/B978-0-12-420118-7.00009-3.
10
Introduction to Sigma Receptors: Their Role in Disease and as Therapeutic Targets.
Adv Exp Med Biol. 2017;964:1-4. doi: 10.1007/978-3-319-50174-1_1.

引用本文的文献

1
Pharmacological and Pathological Implications of Sigma-1 Receptor in Neurodegenerative Diseases.
Biomedicines. 2025 Jun 8;13(6):1409. doi: 10.3390/biomedicines13061409.
3
Discovery and computational studies of piperidine/piperazine-based compounds endowed with sigma receptor affinity.
RSC Med Chem. 2023 Jul 26;14(9):1734-1742. doi: 10.1039/d3md00291h. eCollection 2023 Sep 19.
4
Targeting Sigma-1 Receptor: A Promising Strategy in the Treatment of Parkinson's Disease.
Neurochem Res. 2023 Oct;48(10):2925-2935. doi: 10.1007/s11064-023-03960-6. Epub 2023 May 31.
5
The Sigma Enigma: A Narrative Review of Sigma Receptors.
Cureus. 2023 Mar 4;15(3):e35756. doi: 10.7759/cureus.35756. eCollection 2023 Mar.
6
Generation of Sigmar1 conditional knockout mouse using CRISPR-Cas9 gene targeting.
Genesis. 2022 Jul;60(6-7):e23487. doi: 10.1002/dvg.23487. Epub 2022 May 28.
8
Noscapine, an Emerging Medication for Different Diseases: A Mechanistic Review.
Evid Based Complement Alternat Med. 2021 Nov 29;2021:8402517. doi: 10.1155/2021/8402517. eCollection 2021.

本文引用的文献

1
Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism.
Brain. 2014 Jul;137(Pt 7):1998-2014. doi: 10.1093/brain/awu107. Epub 2014 Apr 22.
4
Sigma receptor 1 modulates ER stress and Bcl2 in murine retina.
Cell Tissue Res. 2014 Apr;356(1):15-27. doi: 10.1007/s00441-013-1774-8. Epub 2014 Jan 28.
6
The σ-1 receptor interacts directly with GluN1 but not GluN2A in the GluN1/GluN2A NMDA receptor.
J Neurosci. 2013 Nov 13;33(46):18219-24. doi: 10.1523/JNEUROSCI.3360-13.2013.
7
Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival.
PLoS One. 2013 Oct 18;8(10):e76941. doi: 10.1371/journal.pone.0076941. eCollection 2013.
9
Afobazole activation of σ-1 receptors modulates neuronal responses to amyloid-β25-35.
J Pharmacol Exp Ther. 2013 Nov;347(2):468-77. doi: 10.1124/jpet.113.208330. Epub 2013 Sep 4.
10
Stimulation of sigma receptors with afobazole blocks activation of microglia and reduces toxicity caused by amyloid-β25-35.
J Pharmacol Exp Ther. 2013 Nov;347(2):458-67. doi: 10.1124/jpet.113.208348. Epub 2013 Sep 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验